NEPHROS, INC. Deferred Income Tax Expense (Benefit)
NEPHROS, INC. (NEPH) reported Deferred Income Tax Expense (Benefit) of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-03.
Discontinued › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2022-03-03
- NEPHROS, INC. deferred income tax expense (benefit) for fiscal 2021 was $0.00.
- NEPHROS, INC. deferred income tax expense (benefit) for fiscal 2020 was $0.00.
| Period end | Deferred Income Tax Expense (Benefit) 12 month |
|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-03-03 |
| 2020-12-31 | $0.00 10-K · filed 2022-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sensus Healthcare, Inc. (SRTS) | United States | $0.048B | -3.24 |
| SANUWAVE Health, Inc. (SNWV) | United States | $0.041B | 5.47 |
| Spectral AI, Inc. (MDAI) | United States | $0.052B | |
| Xtant Medical Holdings, Inc. (XTNT) | United States | $0.053B | |
| TELA Bio, Inc. (TELA) | United States | $0.057B | -0.82 |
| InspireMD, Inc. (NSPR) | $0.033B | ||
| PAVmed Inc. (PAVM) | United States | $0.031B | -3.00 |
| Glucotrack, Inc. (GCTK) | United States | $0.027B | |
| ACCURAY INC (ARAY) | United States | $0.027B | -0.63 |
| DarioHealth Corp. (DRIO) | $0.066B | -1.39 |